Bajaj Broking's December Picks Revealed: Max Healthcare & SGBS Life Sciences Lead Amidst Market Watch!

Market Insights and Top Stock Picks for December

Bajaj Broking Research has released its latest market analysis and stock recommendations for December 19, 2025. The firm has identified Max Healthcare Institute Limited and SGBS Life Sciences Limited, referred to as Sagility in the report, as its top investment picks for the upcoming period.

The report also offers a strategic outlook on India's key benchmark indices, Nifty and Bank Nifty, providing guidance on potential movements and critical levels to watch.

Index View: NIFTY

• The Nifty is currently trading around the 25,800 level, displaying a range-bound movement with a corrective bias.
• Domestic markets are being influenced by global risk-off sentiment, persistent Foreign Institutional Investor (FII) selling, a softer rupee, and ongoing uncertainties in US-India trade talks.
• Key support for the Nifty is identified in the 25,700–25,800 band, aligning with the 50-day Exponential Moving Average (EMA), last week's low, and a significant retracement zone.
• The index is expected to consolidate within the 25,700–26,300 range, with a decisive breakout or breakdown to dictate the next directional move.
• A close below 25,700 could lead to a decline towards the 100-day EMA around 25,400, while immediate resistance is at 26,000, with upside potential towards 26,200-26,300 upon a move above it.

NIFTY BANK Outlook

• The Bank Nifty has been consolidating, digesting recent strong gains within a 1500-point range over the last four weeks.
• The index is anticipated to extend this consolidation and form a base within the 58,500-60,100 range in the coming weeks.
• A sustained strength above the current week's high of 59,500 could pave the way for further upside towards 60,400.
• The recent two-month uptrend appears well-channeled, indicating sustained demand at elevated levels.
• Key support is positioned at 58,300-58,600, coinciding with the 50-day EMA and a recent breakout area. Holding above this support is crucial for maintaining a positive short-term bias.

Stock Recommendation: Max Healthcare Institute Limited

• Bajaj Broking recommends a buy for Max Healthcare Institute Limited in the range of ₹1040-1060.
• A target price of ₹1218 is set, projecting a potential return of 16% over a 12-month period.
• The recommendation is driven by a visible and Return on Capital Employed (ROCE)-accretive expansion cycle, sustained improvements in occupancy and Average Revenue Per Occupied Bed (ARPOB) mix, and strengthening cash flows.
• Management's strategy focuses on brownfield expansion, disciplined asset-light growth, and leveraging operating efficiency from new and greenfield units.
• Growth is supported by a pipeline of phased brownfield additions, new greenfield hospitals, and asset-light facilities. Scaling of Max Lab also adds diversified, capital-light growth.
• Valuation is based on applying a 28x Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization (EV/EBITDA) multiple to projected FY28 earnings.

Stock Recommendation: SGBS Life Sciences Limited (Sagility)

• The firm suggests buying SGBS Life Sciences Limited in the range of ₹49.50-51.50.
• A target price of ₹56 is set, with a stop loss at ₹47, aiming for an 11% return within a 3-month timeframe.
• The stock is in a strong uptrend, consistently trading above its short- and long-term averages and forming higher highs and higher lows on long-term charts.
• It is currently breaking above its previous three weeks' highs, presenting a fresh entry opportunity.
• The stock has shown a shallow retracement, taking seven weeks to retrace only 61.8% of its preceding five-week rally (from ₹42 to ₹58), indicating a higher base formation and a positive overall structure.
• The target of ₹56 is based on an anticipated 80% retracement of the recent decline.

Impact

• These recommendations can influence investor decisions, potentially driving price movements for Max Healthcare Institute Limited and SGBS Life Sciences Limited.
• The detailed index analysis provides investors with a framework for navigating market volatility and identifying potential trading ranges for Nifty and Bank Nifty.
• The report's insights may foster cautious optimism among investors, depending on their risk appetite.
• Impact Rating: 7/10

Difficult Terms Explained

• FII (Foreign Institutional Investor): Overseas entities that invest in the financial markets of another country.
• ROCE (Return on Capital Employed): A profitability ratio that measures how efficiently a company uses its capital to generate profits.
• ARPOB (Average Revenue Per Occupied Bed): A metric used in healthcare to calculate the average revenue generated per day for each occupied hospital bed.
• EV/EBITDA (Enterprise Value to EBITDA): A valuation multiple used to compare companies within the same sector, reflecting a company's total value relative to its operating profit.
• EMA (Exponential Moving Average): A type of moving average that places greater weight and significance on the most recent data points.
• Retracement: In technical analysis, a temporary reversal of a price trend, often preceding a continuation of the main trend.
• Case-mix enrichment: A strategy in healthcare to attract and treat more complex, higher-revenue-generating patient cases.